"Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they have drawbacks. Their effect may not last after discontinuing use, and side effects including osteoporosis and muscle loss have raised concerns about long-term harms. They also induce nausea, which can make it difficult to stay the course of treatment."
"Now Tufts researchers led by Krishna Kumar, Robinson Professor of Chemistry, have designed a new, next-generation compound with hopes that it could be more effective with fewer side effects, which they report in a paper in the Journal of the American Chemical Society. While weight loss drugs currently on the market and in development target one, two, or even three hormone receptors related to glucose metabolism and the desire to eat,"
A new four-in-one hormone compound aims to deliver lasting, surgery-level weight loss while reducing common side effects. GLP-1–based drugs like Ozempic and Wegovy are used by over 15 million U.S. adults but can cause nausea, bone density loss, muscle loss, and weight regain after discontinuation. Current therapies target one to three hormone receptors involved in appetite and glucose metabolism; adding a fourth receptor target could further enhance metabolic control and appetite suppression. The post-meal hormonal 'fuel gauge' involves GLP-1 stimulating insulin release and glucose uptake in tissues, lowering blood glucose. Multi-receptor agonism seeks more durable efficacy with fewer adverse effects.
Read at ScienceDaily
Unable to calculate read time
Collection
[
|
...
]